Shachi Patel
Overview
Explore the profile of Shachi Patel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
82
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Davies M, van der Meer P, Verma S, Patel S, Chinnakondepalli K, Borlaug B, et al.
Lancet Diabetes Endocrinol
. 2025 Jan;
13(3):196-209.
PMID: 39848268
Background: About half of patients with heart failure with mildly reduced or preserved ejection fraction (HFpEF) have type 2 diabetes. In the STEP-HFpEF DM trial of adults with obesity-related HFpEF...
2.
Ambrosy A, Sauer A, Patel S, Windsor S, Borlaug B, Husain M, et al.
ESC Heart Fail
. 2024 Dec;
PMID: 39716939
Aims: Sodium-glucose co-transporter-2 (SGLT2) inhibitors improve health status and outcomes in the setting of heart failure (HF) across the range of ejection fraction (EF). Baseline kidney disease is common in...
3.
Kosiborod M, Cherney D, Desai A, Testani J, Verma S, Chinnakondepalli K, et al.
J Am Coll Cardiol
. 2024 Nov;
85(10):971-984.
PMID: 39566872
Background: Mineralocorticoid receptor antagonists (MRA) improve outcomes in patients with heart failure and reduced ejection fraction (HFrEF) but are underused in clinical practice. Observational data suggest that hyperkalemia is the...
4.
Selvaraj S, Patel S, Sauer A, McGarrah R, Jones P, Kwee L, et al.
Circ Heart Fail
. 2024 Oct;
17(11):e011980.
PMID: 39421941
Background: Mechanisms of benefit with SGLT2is (sodium-glucose cotransporter-2 inhibitors) in heart failure (HF) remain incompletely characterized. Dapagliflozin alters ketone and fatty acid metabolism in HF with reduced ejection fraction though...
5.
Patel S, Rana K, Arya P, Nelson J, Hernandez V, Minakova V
J Cancer Prev
. 2024 Oct;
29(3):58-68.
PMID: 39398111
Cancer remains to be a pervasive disease as traditional treatments have plateaued in efficacy. Anticancer research continues to grow in an effort to find novel preventive and treatment measures for...
6.
Schou M, Petrie M, Borlaug B, Butler J, Davies M, Kitzman D, et al.
J Am Coll Cardiol
. 2024 Jun;
84(3):247-257.
PMID: 38913004
Background: In the Semaglutide Treatment Effect in People with obesity and HFpEF (STEP-HFpEF) program, semaglutide improved heart failure (HF)-related symptoms, physical limitations, and exercise function, and reduced bodyweight in patients...
7.
Verma S, Butler J, Borlaug B, Davies M, Kitzman D, Shah S, et al.
J Am Coll Cardiol
. 2024 Jun;
84(9):773-785.
PMID: 38913003
Background: More women than men have heart failure with preserved ejection fraction (HFpEF). Objectives: The purpose of this study was to assess baseline characteristics and treatment effect of semaglutide by...
8.
Shah S, Sharma K, Borlaug B, Butler J, Davies M, Kitzman D, et al.
Eur Heart J
. 2024 May;
45(35):3254-3269.
PMID: 38739118
Background And Aims: In the STEP-HFpEF trial programme, treatment with semaglutide resulted in multiple beneficial effects in patients with obesity-related heart failure with preserved ejection fraction (HFpEF). Efficacy may vary...
9.
Selvaraj S, Patel S, Sauer A, McGarrah R, Jones P, Kwee L, et al.
JACC Heart Fail
. 2024 Apr;
12(6):999-1011.
PMID: 38639697
Background: Although sodium glucose co-transporter 2 inhibitors (SGLT2is) improve heart failure (HF)-related symptoms and outcomes in HF with preserved ejection fraction (HFpEF), underlying mechanisms remain unclear. In HF with reduced...
10.
Amalraj S, Pittman S, Patel S, Thompson J, Nangia A
Urol Pract
. 2024 Jan;
11(2):324-332.
PMID: 38277176
Introduction: Our study examines the factors associated with urologist availability for younger and older men across the country over a period of 18 years from 2000 to 2018. Methods: The...